Chemoimmunotherapy with weekly cisplatin and etoposide plus S.C. rIL-2 plus oral medroxyprogesterone acetate (MPA) in stage HIB-IV NSCLC: Preliminary results on clinical response and on immunologic assessment
Titel:
Chemoimmunotherapy with weekly cisplatin and etoposide plus S.C. rIL-2 plus oral medroxyprogesterone acetate (MPA) in stage HIB-IV NSCLC: Preliminary results on clinical response and on immunologic assessment
Auteur:
Mantovani, G. Macció, A. Lai, P. Esu, S. Massa, E. Ghiani, M. Astara, G. Mança, G. Massa, D. Lampis, B. Succu, G. Pisano, M. Versace, R. Pusceddu, G.